Compare Stocks: MGTX, LGND, GRFS, and ACAD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.11 -2.1%	$26.79	$19.69 ▼ $30.96	$5.02B	0.81	1.79 million shs	1.53 million shs
GRFS Grifols	$7.69 -1.7%	$7.63	$6.96 ▼ $10.23	$5.23B	0.67	386,747 shs	322,332 shs
LGND Ligand Pharmaceuticals	$280.49 -1.4%	$297.75	$160.05 ▼ $326.63	$5.59B	1.13	235,814 shs	127,695 shs
MGTX MeiraGTx	$13.82 -2.3%	$12.98	$6.62 ▼ $15.35	$1.33B	1.23	627,175 shs	914,208 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-1.32%	+9.64%	+34.40%	+9.56%
GRFS Grifols	0.00%	-3.88%	-6.22%	-2.04%	-21.53%
LGND Ligand Pharmaceuticals	0.00%	-2.03%	-5.33%	+20.92%	+76.30%
MGTX MeiraGTx	0.00%	-3.63%	+15.36%	+29.70%	+85.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.11 -2.1%	$26.79	$19.69 ▼ $30.96	$5.02B	0.81	1.79 million shs	1.53 million shs
GRFS Grifols	$7.69 -1.7%	$7.63	$6.96 ▼ $10.23	$5.23B	0.67	386,747 shs	322,332 shs
LGND Ligand Pharmaceuticals	$280.49 -1.4%	$297.75	$160.05 ▼ $326.63	$5.59B	1.13	235,814 shs	127,695 shs
MGTX MeiraGTx	$13.82 -2.3%	$12.98	$6.62 ▼ $15.35	$1.33B	1.23	627,175 shs	914,208 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-1.32%	+9.64%	+34.40%	+9.56%
GRFS Grifols	0.00%	-3.88%	-6.22%	-2.04%	-21.53%
LGND Ligand Pharmaceuticals	0.00%	-2.03%	-5.33%	+20.92%	+76.30%
MGTX MeiraGTx	0.00%	-3.63%	+15.36%	+29.70%	+85.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	18.04% Upside
GRFS Grifols	1.67	Reduce	$10.00	30.04% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$335.75	19.70% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	89.34% Upside

Current Analyst Ratings Breakdown

Latest MGTX, LGND, GRFS, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/14/2026	LGND Ligand Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$330.00
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/11/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Buy (B-)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.68	$0.89 per share	32.81	$7.58 per share	3.84
GRFS Grifols	$8.51B	0.61	$1.42 per share	5.43	$13.63 per share	0.56
LGND Ligand Pharmaceuticals	$268.09M	20.86	$7.85 per share	35.72	$48.53 per share	5.78
MGTX MeiraGTx	$397.50M	3.34	N/A	N/A	$2.25 per share	6.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.11	29.70	21.71	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	40.47	5.87	0.28	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	30.00	33.12	2.25	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	19.46	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)

Latest MGTX, LGND, GRFS, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.17%	N/A	47.37%	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Latest MGTX, LGND, GRFS, and ACAD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
GRFS Grifols	1.10	2.37	0.81
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
MGTX MeiraGTx	0.46	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
GRFS Grifols	N/A
LGND Ligand Pharmaceuticals	91.28%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
GRFS Grifols	0.19%
LGND Ligand Pharmaceuticals	5.60%
MGTX MeiraGTx	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
LGND Ligand Pharmaceuticals	80	19.94 million	18.82 million	Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable

MGTX, LGND, GRFS, and ACAD Headlines

Recent News About These Companies

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

August 26, 2026 | prnewswire.com

Tocqueville Asset Management L.P. Makes New $1.05 Million Investment in MeiraGTx Holdings PLC $MGTX

August 21, 2026 | marketbeat.com

What Does MeiraGTx (NASDAQ:MGTX) Reveal About Nasdaq Biotech Trends?

August 19, 2026 | kalkinemedia.comK

Insider Selling: MeiraGTx (NASDAQ:MGTX) CEO Sells $859,320.00 in Stock

August 19, 2026 | insidertrades.com

Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock

August 18, 2026 | marketbeat.com

FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright

August 17, 2026 | marketbeat.com

Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX

August 16, 2026 | marketbeat.com

What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal?

August 15, 2026 | uk.finance.yahoo.com

MeiraGTx (NASDAQ:MGTX) Upgraded by Zacks Research to "Strong-Buy" Rating

August 15, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to "Buy" Rating

August 15, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Trading 8.4% Higher Following Strong Earnings

August 14, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada

August 14, 2026 | marketbeat.com

MeiraGTx Swings to Q2 Profit, Revenue Rises

August 14, 2026 | finance.yahoo.com

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

August 14, 2026 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS

August 13, 2026 | marketbeat.com

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

August 13, 2026 | zacks.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Up on Strong Earnings

August 13, 2026 | marketbeat.com

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

August 13, 2026 | globenewswire.com

MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of "Moderate Buy" by Brokerages

August 13, 2026 | marketbeat.com

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

August 11, 2026 | prnewswire.com

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX, LGND, GRFS, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.11 -0.62 (-2.09%)

As of 08/28/2026 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.69 -0.13 (-1.66%)

As of 08/28/2026 04:00 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Ligand Pharmaceuticals NASDAQ:LGND

$280.49 -4.03 (-1.42%)

As of 08/28/2026 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MeiraGTx NASDAQ:MGTX

$13.82 -0.32 (-2.26%)

As of 08/28/2026 04:00 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGTX, LGND, GRFS, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGTX, LGND, GRFS, and ACAD Earnings

Compare Dividends

Latest MGTX, LGND, GRFS, and ACAD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGTX, LGND, GRFS, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX, LGND, GRFS, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Grifols NASDAQ:GRFS

Ligand Pharmaceuticals NASDAQ:LGND

MeiraGTx NASDAQ:MGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGTX, LGND, GRFS, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGTX, LGND, GRFS, and ACAD Earnings

Compare Dividends

Latest MGTX, LGND, GRFS, and ACAD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGTX, LGND, GRFS, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX, LGND, GRFS, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Grifols NASDAQ:GRFS

Ligand Pharmaceuticals NASDAQ:LGND

MeiraGTx NASDAQ:MGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools